ADRs End Mostly Higher, AstraZeneca and atai Life Sciences Trade Actively

By Denny Jacob

International stocks trading in New York closed mostly higher on Tuesday.

The S&P/BNY Mellon index of American depositary receipts edged up 1.4% to 123.62. The European index gained 1.5% to 121.37. The Asian index ticked up 1.5% to 135.64. The Latin American index ticked down 0.4% to 186.28, while the emerging-markets index moved up 0.8% to 233.10.

AstraZeneca PLC was among those whose ADRs traded actively.

The pharmaceutical giant moved up 1.3% after the company said that a Phase 3 trial of its Fasenra treatment for eosinophilic esophagitis passed one dual-primary endpoint but failed the other.

Clinical-stage biopharmaceutical company atai Life Sciences gained 4.5% after it said it completed the enrollment of its Phase 2a clinical trial of PCN-101, a stereoisomer of ketamine being developed for treatment-resistant depression, with topline results expected around 2022 year-end.

Write to Denny Jacob at [e-mail]

(END) Dow Jones Newswires

10-25-22 1827ET